Skip to main content

CORRECTION article

Front. Cell. Infect. Microbiol., 24 August 2023
Sec. Microbial Vaccines
Volume 13 - 2023 | https://doi.org/10.3389/fcimb.2023.1264974
This article is part of the Research Topic Antiviral Monoclonal Antibody Therapies View all 5 articles

Corrigendum: A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022

This article is a correction to:

  1. A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022

    1. Read original article
Kaikai Yu&#x;Kaikai Yu1†Bin Liu&#x;Bin Liu3†Haotian Yu&#x;Haotian Yu1†Chengbiao SunChengbiao Sun1Xuefeng WangXuefeng Wang1Guorui LiGuorui Li4Mingxin DongMingxin Dong1Yan WangYan Wang1Jianxu ZhangJianxu Zhang1Na Xu*Na Xu2*Wensen Liu*Wensen Liu1*
  • 1Changchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China
  • 2Academic Affairs Office, Jilin Medical University, Jilin, Jilin, China
  • 3State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
  • 4College of Life Sciences and Food Engineering, Inner Mongolia Minzu University, Tongliao, China

A corrigendum on
A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022

by Yu K, Liu B, Yu H, Sun C, Wang X, Li G, Dong M, Wang Y, Zhang J, Xu N and Liu W (2023) Front. Cell. Infect. Microbiol. 13:1155293. doi: 10.3389/fcimb.2023.1155293

Error in Author List

In the published article, several of the authors were labeled with the wrong affiliation. The corrected author list appears below.

Kaikai Yu1†, Bin Liu3†, Haotian Yu1†, Chengbiao Sun1, Xuefeng Wang1, Guorui Li4, Mingxin Dong1, Yan Wang1, Jianxu Zhang1, Na Xu2* and Wensen Liu1*

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: SARS-CoV-2, COVID-19, single-chain variable fragment, bispecific antibody, Omicron variant

Citation: Yu K, Liu B, Yu H, Sun C, Wang X, Li G, Dong M, Wang Y, Zhang J, Xu N and Liu W (2023) Corrigendum: A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022. Front. Cell. Infect. Microbiol. 13:1264974. doi: 10.3389/fcimb.2023.1264974

Received: 21 July 2023; Accepted: 14 August 2023;
Published: 24 August 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Yu, Liu, Yu, Sun, Wang, Li, Dong, Wang, Zhang, Xu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wensen Liu, liuws85952@163.com; Na Xu, xunajlu@sina.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.